Journal List > J Rheum Dis > v.22(4) > 1064196

Moon and Min: Immunoglobulin G4-Related Disease

Abstract

Immunoglobulin G4-related disease (IgG4-RD) is an emerging immunemediated fibro-inflammatory disorder which can involve any organ. The main characteristics of IgG4-RD are increased serum IgG4 concentration, abundant IgG4+ plasma cells in affected tissues, and painless swollen organs often without general symptoms. Typical pathology features of IgG4-RD are lymphoplasmacytic infiltration, dense storiform fibrosis, and obliterative pheblitis. The pathogenesis of IgG4-RD remains elu-sive, but involvement of excess production of type 2 T helper cells, regulatory T-cell cytokines, and B-cell activating factor in the development of IgG4-RD has been suggested. Diagnosis of IgG4-RD can be made on the basis of serological, imaging, particularly histopathological findings. Glucocorticoid is the first-line therapy for patients with multiple organ dysfunction and clinical symptoms. Drugs such as azathioprine, mycophenolate mofetil, methotrexate, and cyclophosphamide can be used as ste-roid-sparing agents. Rituximab is reported to be an effective therapy for treatment of IgG4-RD, even without concomitant glucocorticoid therapy. This review summarizes current concepts on pathophysiology, clinical manifestations, and treatment of IgG4-RD.

REFERENCES

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012; 366:539–51.
crossref
2. Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001; 344:732–8.
crossref
3. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol. 2003; 38:982–4.
crossref
4. Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012; 64:3061–7.
crossref
5. Uchida K, Masamune A, Shimosegawa T, Okazaki K. Prevalence of IgG4-related disease in Japan based on nationwide survey in 2009. Int J Rheumatol. 2012; 2012; 358371.
crossref
6. Khosroshahi A, Stone JH. A clinical overview of IgG4-rela-ted systemic disease. Curr Opin Rheumatol. 2011; 23:57–66.
crossref
7. Tanaka A, Moriyama M, Nakashima H, Miyake K, Hayashida JN, Maehara T, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis Rheum. 2012; 64:254–63.
crossref
8. Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol. 2014; 9:315–47.
crossref
9. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004; 4:583–94.
crossref
10. Akiyama M, Suzuki K, Yamaoka K, Yasuoka H, Takeshita M, Kaneko Y, et al. Number of circulating T follicular helper 2 cells correlates with IgG4 and IL-4 levels and plasmablast numbers in IgG4-related disease. Arthritis Rheumatol. 2015 May 18; [Epub].DOI: DOI: 10.1002/art.39209.
11. Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015; 181:191–206.
crossref
12. Lin W, Jin L, Chen H, Wu Q, Fei Y, Zheng W, et al. B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences. Arthritis Res Ther. 2014; 16:R118.
crossref
13. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis. 2007; 66:790–7.
14. Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015; 74:190–5.
crossref
15. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3:23–35.
crossref
16. Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz's disease. Clin Immunol. 2015; 156:9–18.
crossref
17. Watanabe T, Yamashita K, Fujikawa S, Sakurai T, Kudo M, Shiokawa M, et al. Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum. 2012; 64:914–24.
crossref
18. Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014; 10:474–83.
crossref
19. Padigel UM, Hess JA, Lee JJ, Lok JB, Nolan TJ, Schad GA, et al. Eosinophils act as antigen-presenting cells to induce immunity to Strongyloides stercoralis in mice. J Infect Dis. 2007; 196:1844–51.
20. Watanabe T, Yamashita K, Sakurai T, Kudo M, Shiokawa M, Uza N, et al. Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol. 2013; 48:247–53.
crossref
21. Bindon CI, Hale G, Brüggemann M, Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988; 168:127–42.
crossref
22. Fellrath JM, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 2003; 111:854–61.
crossref
23. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol. 2004; 172:3252–9.
crossref
24. Saeki T, Nishi S, Imai N, Ito T, Yamazaki H, Kawano M, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010; 78:1016–23.
crossref
25. Detlefsen S, Bräsen JH, Zamboni G, Capelli P, Klöppel G. Deposition of complement C3c, immunoglobulin (Ig)G4 and IgG at the basement membrane of pancreatic ducts and acini in autoimmune pancreatitis. Histopathology. 2010; 57:825–35.
crossref
26. Cornell LD, Chicano SL, Deshpande V, Collins AB, Selig MK, Lauwers GY, et al. Pseudotumors due to IgG4 immune-complex tubulointerstitial nephritis associated with autoimmune pancreatocentric disease. Am J Surg Pathol. 2007; 31:1586–97.
crossref
27. Holland M, Hewins P, Goodall M, Adu D, Jefferis R, Savage CO. Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass. Clin Exp Immunol. 2004; 138:183–92.
crossref
28. Green MG, Bystryn JC. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 anti-desmoglein 1 and antidesmoglein 3 antibodies in pemphi-gus vulgaris. Arch Dermatol. 2008; 144:1621–4.
crossref
29. Saeki T, Ito T, Youkou A, Ishiguro H, Sato N, Yamazaki H, et al. Thrombotic thrombocytopenic purpura in IgG4-rela-ted disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13. Arthritis Care Res (Hoboken). 2011; 63:1209–12.
crossref
30. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012; 25:1181–92.
crossref
31. Deshpande V. The pathology of IgG4-related disease: critical issues and challenges. Semin Diagn Pathol. 2012; 29:191–6.
crossref
32. Deshpande V, Khosroshahi A, Nielsen GP, Hamilos DL, Stone JH. Eosinophilic angiocentric fibrosis is a form of IgG4-related systemic disease. Am J Surg Pathol. 2011; 35:701–6.
crossref
33. Deshpande V, Gupta R, Sainani N, Sahani DV, Virk R, Ferrone C, et al. Subclassification of autoimmune pancreatitis: a histologic classification with clinical significance. Am J Surg Pathol. 2011; 35:26–35.
34. Kamisawa T, Takuma K, Egawa N, Tsuruta K, Sasaki T. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol. 2010; 7:401–9.
crossref
35. Kamisawa T, Chen PY, Tu Y, Nakajima H, Egawa N, Tsuruta K, et al. Pancreatic cancer with a high serum IgG4 concentration. World J Gastroenterol. 2006; 12:6225–8.
crossref
36. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010; 139:140–8.
crossref
37. Kim JH, Kim MH, Byun JH, Lee SS, Lee SJ, Park SH, et al. Diagnostic strategy for differentiating autoimmune pancreatitis from pancreatic cancer: is an endoscopic retrograde pancreatography essential? Pancreas. 2012; 41:639–47.
38. Uehara T, Masumoto J, Yoshizawa A, Kobayashi Y, Hamano H, Kawa S, et al. IgG4-related disease-like fibrosis as an indicator of IgG4-related lymphadenopathy. Ann Diagn Pathol. 2013; 17:416–20.
crossref
39. Himi T, Takano K, Yamamoto M, Naishiro Y, Takahashi H. A novel concept of Mikulicz's disease as IgG4-related disease. Auris Nasus Larynx. 2012; 39:9–17.
crossref
40. Yao Q, Wu G, Hoschar A. IgG4-related Mikulicz's disease is a multiorgan lymphoproliferative disease distinct from Sjögren's syndrome: a Caucasian patient and literature review. Clin Exp Rheumatol. 2013; 31:289–94.
41. Furukawa S, Moriyama M, Kawano S, Tanaka A, Maehara T, Hayashida JN, et al. Clinical relevance of Küttner tumour and IgG4-related dacryoadenitis and sialoadenitis. Oral Dis. 2015; 21:257–62.
42. Geyer JT, Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol. 2011; 23:95–101.
crossref
43. Sato Y, Yoshino T. IgG4-related lymphadenopathy. Int J Rheumatol. 2012; 2012; 572539.
crossref
44. Sato Y, Inoue D, Asano N, Takata K, Asaoku H, Maeda Y, et al. Association between IgG4-related disease and progressively transformed germinal centers of lymph nodes. Mod Pathol. 2012; 25:956–67.
crossref
45. Ferry JA. IgG4-related lymphadenopathy and IgG4-related lymphoma: moving targets. Diagn Histopathol. 2013; 19:128–39.
crossref
46. Hicks J, Flaitz C. Progressive transformation of germinal centers: review of histopathologic and clinical features. Int J Pediatr Otorhinolaryngol. 2002; 65:195–202.
crossref
47. Grimm KE, Barry TS, Chizhevsky V, Hii A, Weiss LM, Siddiqi IN, et al. Histopathological findings in 29 lymph node biopsies with increased IgG4 plasma cells. Mod Pathol. 2012; 25:480–91.
crossref
48. Saeki T, Kawano M. IgG4-related kidney disease. Kidney Int. 2014; 85:251–7.
crossref
49. Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013; 84:826–33.
crossref
50. Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, et al. Proposal for diagnostic criteria for IgG4-rela-ted kidney disease. Clin Exp Nephrol. 2011; 15:615–26.
crossref
51. Yamaguchi Y, Kanetsuna Y, Honda K, Yamanaka N, Kawano M, Nagata M. Japanese Study Group on IgG4-related nephropathy. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2012; 43:536–49.
crossref
52. Khosroshahi A, Ayalon R, Beck LH Jr, Salant DJ, Bloch DB, Stone JH. IgG4-related disease is not associated with anti-body to the phospholipase A2 receptor. Int J Rheumatol. 2012; 2012; 139409.
crossref
53. Wallace ZS, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum. 2014; 43:806–17.
crossref
54. Suzuki M, Nakamaru Y, Akazawa S, Mizumachi T, Maeda M, Takagi D, et al. Nasal manifestations of immunoglobulin G4-related disease. Laryngoscope. 2013; 123:829–34.
crossref
55. Takagi D, Nakamaru Y, Fukuda S. Otologic manifestations of immunoglobulin G4-related disease. Ann Otol Rhinol Laryngol. 2014; 123:420–4.
crossref
56. Deshpande V, Huck A, Ooi E, Stone JH, Faquin WC, Nielsen GP. Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease. J Clin Pathol. 2012; 65:725–8.
crossref
57. Watanabe T, Maruyama M, Ito T, Fujinaga Y, Ozaki Y, Maruyama M, et al. Clinical features of a new disease concept, IgG4-related thyroiditis. Scand J Rheumatol. 2013; 42:325–30.
crossref
58. Zen Y, Inoue D, Kitao A, Onodera M, Abo H, Miyayama S, et al. IgG4-related lung and pleural disease: a clinicopathologic study of 21 cases. Am J Surg Pathol. 2009; 33:1886–93.
crossref
59. Ryu JH, Sekiguchi H, Yi ES. Pulmonary manifestations of immunoglobulin G4-related sclerosing disease. Eur Respir J. 2012; 39:180–6.
crossref
60. Kasashima S, Zen Y, Kawashima A, Endo M, Matsumoto Y, Kasashima F, et al. A clinicopathologic study of immunoglobulin G4-related sclerosing disease of the thoracic aorta. J Vasc Surg. 2010; 52:1587–95.
crossref
61. Inokuchi G, Hayakawa M, Kishimoto T, Makino Y, Iwase H. A suspected case of coronary periarteritis due to IgG4-related disease as a cause of ischemic heart disease. Forensic Sci Med Pathol. 2014; 10:103–8.
crossref
62. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015; 385:1460–71.
crossref
63. Zen Y, Kasashima S, Inoue D. Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease. Semin Diagn Pathol. 2012; 29:212–8.
crossref
64. Khosroshahi A, Carruthers MN, Stone JH, Shinagare S, Sainani N, Hasserjian RP, et al. Rethinking Ormond's disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 2013; 92:82–91.
65. Stone JH. L45. Aortitis, retroperitoneal fibrosis, and IgG4-related disease. Presse Med. 2013; 42:622–5.
crossref
66. Castelein T, Coudyzer W, Blockmans D. IgG4-related periaortitis vs idiopathic periaortitis: is there a role for atherosclerotic plaque in the pathogenesis of IgG4-related periaortitis? Rheumatology (Oxford). 2015; 54:1250–6.
67. Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev. 2014; 13:1203–10.
crossref
68. Kamisawa T, Nakajima H, Egawa N, Funata N, Tsuruta K, Okamoto A. IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreatology. 2006; 6:132–7.
crossref
69. Lu LX, Della-Torre E, Stone JH, Clark SW. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA Neurol. 2014; 71:785–93.
70. Bando H, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, Matsumoto R, et al. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol. 2013; 170:161–72.
crossref
71. Pieringer H, Parzer I, Wöhrer A, Reis P, Oppl B, Zwerina J. IgG4-related disease: an orphan disease with many faces. Orphanet J Rare Dis. 2014; 9:110.
crossref
72. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012; 22:21–30.
crossref
73. Okazaki K, Umehara H. Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan. Int J Rheumatol. 2012; 2012; 357071.
crossref
74. Ryu JH, Horie R, Sekiguchi H, Peikert T, Yi ES. Spectrum of disorders associated with elevated serum IgG4 levels encountered in clinical practice. Int J Rheumatol. 2012; 2012; 232960.
crossref
75. Boonstra K, Culver EL, de Buy Wenniger LM, van Heerde MJ, van Erpecum KJ, Poen AC, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. 2014; 59:1954–63.
crossref
76. Ohshima K, Sato Y, Yoshino T. A case of IgG4-related dacryoadenitis that regressed without systemic steroid administration. J Clin Exp Hematop. 2013; 53:53–6.
crossref
77. Stone JH. IgG4-related disease: nomenclature, clinical features, and treatment. Semin Diagn Pathol. 2012; 29:177–90.
crossref
78. Shimizu Y, Yamamoto M, Naishiro Y, Sudoh G, Ishigami K, Yajima H, et al. Necessity of early intervention for IgG4-related disease: delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013; 52:679–83.
79. Della-Torre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2014 Aug 20; [Epub].DOI: DOI: 10.1136/annrheumdis-2014-205799.
crossref
80. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol. 2011; 23:67–71.
crossref

Figure 1.
immunoglobulin G (IgG)4 Fab-arm exchange makes bispecific antibodies. The heavy chains of IgG are bound to each other by interchain disulfide bridge. As the disulfide bonds between heavy chains of IgG4 are unstable, IgG4 easily forms intrachain disulfide bonds in the hinge region. Intrachain disulfide bond of IgG4 is linked by noncovalent interaction. When the non-con-valent bonds dissociate, half of one IgG4 molecule (a heavy chain-light chain pair) and half of another IgG4 molecule exchange randomly, forming a Fab-arm exchange. Through such processes, the IgG4 molecule becomes bispecific by acquiring two Fab-arms with different epitope specificity. This bispecific IgG4 molecule, however, loses its ability to form immune complexes as the molecules cannot crosslink antigens.
jrd-22-213f1.tif
Figure 2.
Histological and immunohistochemical findings of biopsy specimens of the lymph node (A) and submandibular gland (B∼E). (A) The germinal centersare predominantly composed of small lymphocytes, centrocytes, centroblasts, and numerous mature plasma cells (H&E, ×200). (B) The storiform pattern of fibrosis is present, indicating dense fibrosis within which lymphocytes, plasma cells, and occasional eosinophils are embedded (H&E, ×100). (C) Veins occluded by inflammatory infiltrate composed of lymphocytes and plasma cells are noted (arrowheads) (H&E, ×200). (D, E) The IgG4+/IgG+ plasma cell ratio is estimated at 90%. D: Immunoglobulin (Ig) G-immunohistochemical stain, E: IgG4-immunohistochemical stain; ×100.
jrd-22-213f2.tif
Table 1.
Characteristics of IgG isotypes
Characteristic IgG1 IgG2 IgG3 IgG4
Serum concentration (mg/dL) 5∼11 1.5∼6 0.2∼1 0.08∼1.4
Complement fixation +++ + +++
Activating Fcγ R binding ++ + ++ ++

Fcγ R: Fc-gamma receptors, IgG: immunoglobulin G.

TOOLS
Similar articles